- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- ROIV
- Stock Information
- Founded
- CELH 2004
- ROIV 2014
- Country
- CELH United States
- ROIV United Kingdom
- Employees
- CELH N/A
- ROIV N/A
- Industry
- CELH Beverages (Production/Distribution)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- ROIV Health Care
- Exchange
- CELH Nasdaq
- ROIV Nasdaq
- Market Cap
- CELH 7.5B
- ROIV 7.8B
- IPO Year
- CELH N/A
- ROIV N/A
- Fundamental
- Price
- CELH $37.88
- ROIV $10.99
- Analyst Decision
- CELH Buy
- ROIV Buy
- Analyst Count
- CELH 17
- ROIV 4
- Target Price
- CELH $47.53
- ROIV $17.50
- AVG Volume (30 Days)
- CELH 7.9M
- ROIV 5.1M
- Earning Date
- CELH 05-06-2025
- ROIV 05-29-2025
- Dividend Yield
- CELH N/A
- ROIV N/A
- EPS Growth
- CELH N/A
- ROIV N/A
- EPS
- CELH 0.32
- ROIV N/A
- Revenue
- CELH $1,329,198,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CELH $60.96
- ROIV N/A
- Revenue Next Year
- CELH $24.98
- ROIV N/A
- P/E Ratio
- CELH $116.61
- ROIV N/A
- Revenue Growth
- CELH N/A
- ROIV N/A
- 52 Week Low
- CELH $21.10
- ROIV $8.73
- 52 Week High
- CELH $80.65
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CELH 55.62
- ROIV 52.59
- Support Level
- CELH $34.10
- ROIV $10.59
- Resistance Level
- CELH $37.70
- ROIV $11.37
- Average True Range (ATR)
- CELH 1.69
- ROIV 0.32
- MACD
- CELH -0.17
- ROIV -0.01
- Stochastic Oscillator
- CELH 64.73
- ROIV 52.23
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.